LivaNova is a global medical technology company focused on improving patient lives through innovative solutions for cardiopulmonary, drug-resistant epilepsy, and difficult-to-treat depression.
LivaNova is dedicated to advancing the quality of life for patients by developing and delivering life-changing medical technologies for the head and heart. The company focuses on areas such as cardiopulmonary support, drug-resistant epilepsy, and difficult-to-treat depression, aiming to offer patients improved well-being and the potential to reclaim their lives. With a commitment to product safety and sustainability, LivaNova operates as a people-oriented company, with employees worldwide dedicated to making a positive impact. They support educational, charitable, and medical-scientific endeavors relevant to their therapeutic areas, including through grants and sponsorships, while also engaging in investigator-initiated research to drive innovation. LivaNova PLC is registered in England and Wales, with its registered office at 20 Eastbourne Terrace, London, W2 6LG, United Kingdom. The company's mission is to treat their work as if lives depend on it, because they do, striving to offer days without seizures, nights of unencumbered sleep, and hearts beating strong and steady.
About
**Who they are** LivaNova is a global medical technology company dedicated to improving patient lives through innovative solutions in cardiopulmonary, drug-resistant epilepsy, and difficult-to-treat depression. They focus on advancing the quality of life for patients through their work.
**Expertise & scope** * Supports educational, charitable, and research endeavors that benefit health and society. * Considers commercial sponsorships for events relevant to LivaNova's therapeutic areas, often in exchange for brand visibility. * Offers support for Investigator Initiated Research (IIR) studies, which are designed and conducted independently by investigators using LivaNova products. This support can be in the form of product, funding, or technical input. * Provides monetary or in-kind educational grants, research grants, and charitable donations for indigent care.
**Reputation / proof points** * Registered in England and Wales, No. 09451374.
Additional information
LivaNova's approach to external support is categorized into several distinct programs. Commercial sponsorships are considered for events aligned with their therapeutic areas, typically involving an exchange for promotional visibility. For donations and grants, the company supports endeavors with a genuine educational or public health function, benefiting society or demonstrating good corporate citizenship. This includes educational grants, research grants, and charitable donations for indigent care. It is important to note that requests for Investigator Initiated Research (IIR) or commercial sponsorships are handled through separate, dedicated channels and are not within the scope of the Donations and Grants Program. Potential applicants should review the specific eligibility requirements for each program.
Key Highlights
Focuses on innovative solutions for cardiopulmonary, drug-resistant epilepsy, and difficult-to-treat depression.
Source
“LivaNova is a global medical technology company focused on improving patient lives through innovative solutions for cardiopulmonary, drug-resistant epilepsy, and difficult-to-treat depression.”
Supports educational, charitable, and medical-scientific advancement endeavors.
Source
“As part of our mission, we support educational, charitable and medical-scientific advancement endeavors that serve a genuine educational or public health function, benefit society or that demonstrate good corporate citizenship.”
Considers commercial sponsorships for events relevant to their therapeutic areas.
Source
“LivaNova's Commercial Teams will consider commercial sponsorship for events that are relevant to LivaNova's therapeutic areas...”
Provides support for Investigator Initiated Research (IIR) involving LivaNova products.
Source
“IIR may be supported by LivaNova in the form of product, funding and/or technical input.”